research Treatment of alopecia areata: An Australian expert consensus statement
Alopecia areata treatment varies, with no optimal method established yet.
Search
for
Sort by
Research
90-120 / 1000+ results 
research An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.
research The use of phosphodiesterase inhibitors for the treatment of alopecia
Caffeine shows promise for treating some types of hair loss, but more research is needed.
research Cytokine-targeted treatment in alopecia areata - new possibilities?
New cytokine-targeted therapies show promise for treating alopecia areata.
research Case Report: Successful treatment of pediatric alopecia universalis with ritlecitinib after failure of baricitinib
Ritlecitinib successfully treated a child's alopecia universalis after baricitinib failed.
research Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
research Guidelines for the Management of Patients with Alopecia Areata in Korea: Part I Topical and Device-based Treatment
The guidelines offer updated treatment recommendations for alopecia areata in Korea using topical and device-based methods.
research Korean Consensus Criteria for the Severity Classification of Alopecia Areata
The criteria help doctors diagnose and treat alopecia areata more effectively.
research New therapies for alopecia areata
New treatments for severe alopecia areata show promise but lack standard approval.
research El papel de los inhibidores de JAK en la alopecia areata: revisión de la literatura
JAK inhibitors help treat alopecia areata but have high recurrence after stopping.
research Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
Upadacitinib effectively treats severe alopecia areata and is safe.
research The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials
The AA-IGA scale reliably measures treatment success in alopecia areata by considering both clinician and patient views.
research Baricitinib regrows hair in adolescents with alopecia areata
Baricitinib helps regrow hair in teens with severe alopecia areata.
research A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.
research Cytokine-Targeting Biologic Therapies for Alopecia Areata: A Comprehensive Review of Mechanism of Action, Clinical Efficacy, and Adverse Events
Dupilumab and ustekinumab are promising treatments for alopecia areata, showing significant hair regrowth.
research Efficacy of Local and Whole‐Body Phototherapy for the Treatment of Various Types of Alopecia Areata
Phototherapy effectively treats certain alopecia areata types, especially if started early.
research Effectiveness and safety of baricitinib in patients with moderate‐to‐severe refractory alopecia areata in real world: An open‐label, single‐center study
Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
research Serum Level of Macrophage Migration Inhibitory Factor (MIF) in Egyptians With Alopecia Areata and Its Relation to the Clinical Severity of the Disease
Higher MIF levels in alopecia areata patients suggest it could be a treatment target and disease predictor.
research Systemic Inflammation Marker Alterations in Severe Alopecia Areata Patients Treated with Janus Kinase Inhibitors
Janus kinase inhibitors reduce inflammation markers in severe alopecia areata patients.
research “‘You lose your hair, what’s the big deal?’ I was so embarrassed, I was so self-conscious, I was so depressed:” a qualitative interview study to understand the psychosocial burden of alopecia areata
Alopecia Areata (AA) causes significant emotional distress, including feelings of embarrassment, depression, and anxiety, and impacts social interactions and daily activities.
research Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials
Regrowing scalp hair improves quality of life and reduces anxiety and depression in severe alopecia areata patients.
research Dupilumab in Inflammatory Skin Diseases: A Systematic Review
Dupilumab effectively treats various inflammatory skin diseases beyond its initial use for atopic dermatitis.
research Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study
Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.
research Efficacy and safety of ritlecitinib, an oral JAK3 /TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis
Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
research From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology
JAK inhibitors are effective for treating moderate-to-severe alopecia areata.
research The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials
JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.
research Revolutionary Approaches to Hair Regrowth: Follicle Neogenesis, Wnt/ß-Catenin Signaling, and Emerging Therapies
New hair regrowth therapies show promise but need more research.
research Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
research Immunopathology and Immunotherapy of Inflammatory Skin Diseases
New targeted immunotherapies are improving treatment for inflammatory skin diseases.
research Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.